Rodríguez-Moranta Francisco, Soriano-Izquierdo Antonio, Guardiola Jordi
Servicio de Gastroenterología, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.
Cir Esp. 2007 Nov;82(5):254-9. doi: 10.1016/s0009-739x(07)71722-0.
Inflammatory bowel disease encompasses a group of diseases with poorly defined etiology that affect the digestive tract. These diseases are characterized by their chronic course and by periods of disease activity, of variable severity, that alternate with periods of clinical remission. In the last few years, inflammatory bowel disease has been the object of intense research, which has increased knowledge of the physiopathogenic mechanisms involved. This has enabled the development of a new generation of biotechnological drugs effective in patients previously considered to be refractory to medical treatment and has allowed the accumulated corticosteroid dose to be reduced and the indications for surgery and hospital admissions to be decreased, thus improving quality of life. In addition, some classical drugs have been demonstrated to be effective in recurrence prevention after surgery for Crohn's disease and in the prevention of dysplasia and colorectal cancer in inflammatory bowel disease.
炎症性肠病包括一组病因不明的影响消化道的疾病。这些疾病的特点是病程慢性，且疾病活动期的严重程度各异，与临床缓解期交替出现。在过去几年中，炎症性肠病一直是深入研究的对象，这增加了对所涉及的生理致病机制的了解。这使得新一代生物技术药物得以开发，这些药物对以前被认为对药物治疗难治的患者有效，还能减少累积使用的皮质类固醇剂量，并减少手术和住院指征，从而提高生活质量。此外，一些经典药物已被证明在克罗恩病手术后预防复发以及预防炎症性肠病的发育异常和结直肠癌方面有效。
